论文部分内容阅读
目的探讨急性冠脉综合征患者普罗布考治疗前后血脂水平、血清氧化低密度脂蛋白(ox-LDL)、基质金属蛋白酶(MMP-2和MMP-9)水平的变化。方法选择急性冠脉综合征住院患者82例,随机分为普罗布考治疗组40例和对照组42例,两组患者均应用常规基础治疗,治疗组加用普罗布考口服。分别于治疗前和治疗4周后抽血查血脂、氧化低密度脂蛋白含量,治疗前和治疗后第3天、7天时血清基质金属蛋白酶(MMP-2和MMP-9)含量。结果同对照组比较,普罗布考治疗组总胆固醇(TC)、低密度脂蛋白(LDL)及甘油三酯(TG)均明显降低;同时普罗布考治疗组氧化低密度脂蛋白(ox-LDL)血清MMP-2和MMP-9含量也明显降低,差异均有统计学意义(P<0.05)。两组患者均未出现严重不良反应。结论普罗布考不仅能有效降低急性冠脉综合征患者的血清TC和LDL水平,同时还能显著降低血清ox-LDL及血清MMP-2和MMP-9水平,具有抗氧化及抗炎作用。
Objective To investigate the changes of serum lipids, serum ox-LDL and MMP-2 and MMP-9 levels in patients with acute coronary syndrome before and after probucol treatment. Methods Eighty-two inpatients with acute coronary syndrome were randomly divided into two groups: 40 cases in probucol group and 42 cases in control group. Both groups were treated with routine basic treatment. The treatment group was treated with probucol orally. Serum levels of matrix metalloproteinases (MMP-2 and MMP-9) were measured before and 4 weeks after treatment, respectively. The levels of serum lipids and LDL-C were measured before treatment and on the 3rd and 7th day after treatment. Results Compared with the control group, the concentrations of total cholesterol (TC), low density lipoprotein (LDL) and triglyceride (TG) in probucol treatment group were significantly decreased. In the probucol treatment group, ox-LDL ) Serum MMP-2 and MMP-9 levels were also significantly lower, the difference was statistically significant (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Probucol can not only effectively reduce the level of serum TC and LDL in patients with acute coronary syndrome, but also decrease the levels of serum ox-LDL, serum MMP-2 and MMP-9, and have anti-oxidation and anti-inflammatory effects.